Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance
Sitamaquine is a 8-aminoquinoline in development for the treatment of visceral leishmaniasis by oral route, no activity being observed on the experimental cutaneous leishmaniasis experimental models. Recent data explain how sitamaquine accumulate in Leishmania parasites, however its molecular target...
Main Authors: | Loiseau P.M., Cojean S., Schrével J. |
---|---|
Format: | Article |
Language: | English |
Published: |
EDP Sciences
2011-05-01
|
Series: | Parasite |
Subjects: | |
Online Access: | http://dx.doi.org/10.1051/parasite/2011182115 |
Similar Items
-
Treatment of experimental leishmaniasis with the immunomodulators, imiquimod and S-28463 : efficacy and mode of action
by: Buates, Sureemas.
Published: (2001) -
Quinoline-Based Hybrid Compounds with Antimalarial Activity
by: Xhamla Nqoro, et al.
Published: (2017-12-01) -
Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh’s National Kala-azar Elimination Programme
by: Md. Sakhawat Hossain, et al.
Published: (2018-08-01) -
Marine Algae as Source of Novel Antileishmanial Drugs: A Review
by: Lauve Rachel Tchokouaha Yamthe, et al.
Published: (2017-10-01) -
THE ACTIVITY OF 4-AMINOQUINOLINE AGAINST PLASMODIUM FALCIPARUM IN SOUTHERN IRAN
by: AV. Manouchehri, et al.
Published: (1973-06-01)